Literature DB >> 8601727

Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin.

S Nagpal1, S Patel, A T Asano, A T Johnson, M Duvic, R A Chandraratna.   

Abstract

Retinoids exert their effect through ligand-dependent transcription factors, retinoic acid receptors (RARalpha, beta, and gamma) and retinoid X receptor (RXRalpha, beta, and gamma), which belong to the superfamily of steroid/thyroid/vitamin D3, nuclear receptors. Using a subtraction hybridization approach, we have identified a cDNA sequence, Tazarotene Induced Gene 1 (TIG1), which is highly upregulated in skin raft cultures by an RARbeta/gamma -selective retinoid AGN 190168 (tazarotene/ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl]nicotinate), which is effective in the treatment of psoriasis. The retinoid-mediated upregulation in the expression of TIG1 was confirmed by Southern and Northern analyses. Upon sequencing, TIG1 was found to be a novel cDNA which encodes a protein of 228 amino acids whose sequence suggests that is a transmembrane protein with a small N-terminal intracellular region, a single membrane-spanning hydrophobic region, and a large C-terminal extracellular region containing a glycosylation signal. We demonstrate that TIG1 is also upregulated by AGN 190168 in skin raft cultures prepared from psoriatic fibroblasts and normal keratinocytes and in primary fibroblast and keratinocyte cultures. We also show that TIG1 is upregulated by retinoic acid receptor but not by retinoid X receptor-specific synthetic retinoids. Finally, we demonstrate that TIG1 is induced by AGN 190168 in psoriatic lesions during the course of clinical treatment of the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8601727     DOI: 10.1111/1523-1747.ep12340668

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  34 in total

1.  Identification of RARRES1 as a core regulator in liver fibrosis.

Authors:  Andreas Teufel; Diana Becker; Susanne N Weber; Steven Dooley; Katja Breitkopf-Heinlein; Thorsten Maass; Katrin Hochrath; Markus Krupp; Jens U Marquardt; Martin Kolb; Bernhard Korn; Christof Niehrs; Tim Zimmermann; Patricio Godoy; Peter R Galle; Frank Lammert
Journal:  J Mol Med (Berl)       Date:  2012-06-06       Impact factor: 4.599

2.  TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.

Authors:  Xiaoping Wang; Hitomi Saso; Takayuki Iwamoto; Weiya Xia; Yun Gong; Lajos Pusztai; Wendy A Woodward; James M Reuben; Steven L Warner; David J Bearss; Gabriel N Hortobagyi; Mien-Chie Hung; Naoto T Ueno
Journal:  Cancer Res       Date:  2013-09-06       Impact factor: 12.701

Review 3.  Tazarotene.

Authors:  R H Foster; R N Brogden; P Benfield
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

4.  Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma.

Authors:  S Nagpal; J Cai; T Zheng; S Patel; R Masood; G Y Lin; S Friant; A Johnson; D L Smith; R A Chandraratna; P S Gill
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

5.  Aberrant TIG1 methylation associated with its decreased expression and clinicopathological significance in hepatocellular carcinoma.

Authors:  Xi-Hua Chen; Wen-Guang Wu; Jian Ding
Journal:  Tumour Biol       Date:  2013-09-05

6.  Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma.

Authors:  Suhail K Mithani; Ian M Smith; Joseph A Califano
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

7.  Soluble RARRES1 induces podocyte apoptosis to promote glomerular disease progression.

Authors:  Anqun Chen; Ye Feng; Han Lai; Wenjun Ju; Zhengzhe Li; Yu Li; Andrew Wang; Quan Hong; Fang Zhong; Chengguo Wei; Jia Fu; Tianjun Guan; Bichen Liu; Matthias Kretzler; Kyung Lee; John Cijiang He
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

8.  Developmentally regulated SMAD2 and SMAD3 utilization directs activin signaling outcomes.

Authors:  Catherine Itman; Chris Small; Michael Griswold; Ankur K Nagaraja; Martin M Matzuk; Chester W Brown; David A Jans; Kate L Loveland
Journal:  Dev Dyn       Date:  2009-07       Impact factor: 3.780

9.  Tumor Suppressor RARRES1 Regulates DLG2, PP2A, VCP, EB1, and Ankrd26.

Authors:  Ziad J Sahab; Michael D Hall; Lihua Zhang; Amrita K Cheema; Stephen W Byers
Journal:  J Cancer       Date:  2010-06-02       Impact factor: 4.207

10.  Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene.

Authors:  D DiSepio; C Ghosn; R L Eckert; A Deucher; N Robinson; M Duvic; R A Chandraratna; S Nagpal
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.